IL-17 Blockade to Decrease irAEs (REPLAY)
NCT07237594
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
4
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Melanoma
Interventions
DRUG:
Secukinumab Injection
Sponsor
Duke University